Radiopharm Theranostics Ltd has released a press release.
Acceleration of RAD204 Phase 1 dose escalation trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference
- Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis
- First patient dosed in Phase IIb imaging for Brain Mets
- New RAD202 data confirms positive tumor uptake
- Half Year Report and Appendix 4D 31 December 2024
Later from Radiopharm Theranostics
- Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)
- ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
- RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
- Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
- RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics